Girts Cimermans CEO, Jennifer Dean CFO February 22, 2023
medmix CONFIDENTIAL
The safe harbor statement under the
US private securities litigation reform act 1995
This presentation may contain forward-looking statements, including but not limited to, projections of financial developments, market activities or future performance of products and solutions, containing risks and uncertainties. These forward-looking statements are subject to change based on known or unknown risks and various other factors, which could cause the actual results or performance to differ materially from the statements made herein.
Note on Alternative Performance Measures (APM): All bridges from reported figures to APM can be found in the financial review of medmix' annual report 2022 and all definitions of APM can be found in
the APM section of medmix' annual report 2022.
medmix CONFIDENTIAL
Business Review
medmix CONFIDENTIAL
2022 highlights
Strong performance with backdrop of volatile geopolitical and market conditions
Record revenue of CHF 477 million, +5.7%1 YoY
22% Adjusted EBITDA margin
CHF 10 million free cash flow
Launch of innovative PiccoJect™, Micro Bristle Applicator and greenLine™ cartridge
New US healthcare facility leased in Atlanta, Georgia
Decisive action taken to ensure Industry customer service
acquisition of company & leasing of new facility in Valencia, Spain
rapid ramp up of alternate production across our existing network
active negotiations to sell the Polish entity
In line with the local for local China strategy, announced our intention to acquire Qiaoyi Plastic Co. LTD, a beauty manufacturing business in Shantou
Proposing a dividend of CHF 0.50 per share
1.
Adjusted for currency effects
5
medmix CONFIDENTIAL
Attachments
Original Link
Original Document
Permalink
Disclaimer
Medmix Ltd. published this content on 22 February 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 February 2023 08:36:11 UTC.
Medmix Systems AG is a Switzerland-based company active in manufacturing of high-precision delivery devices. The Company operates in business areas such as: the dental segment, which provides MIXPAC and transcodent - system solutions that are used to dose, mix and apply various types of dental materials; drug delivery- solutions for the dosage and application of drugs; a surgical segment which provides devices for bone regeneration and tissue healing; an industry segment that specializes in the mixing and dosing of sealants and adhesives through IXPAC , COX and MK; and a beauty segment in which it produces cosmetic applicators through the GEKA brand.
MEDMIX AG 
